



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2026-27/42

July 16, 2026

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 051
Scrip Code - 532523	Scrip Symbol - BIOCON

Subject: Company Statement

Dear Sir/Madam,

Please find enclosed Company Statement w.r.t. **“Biocon Malaysia Receives EMA Approval for New Drug Product Fill Finish Unit for Insulins”**.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328

Encl: Company Statement



NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

**Biocon Malaysia Receives EMA Approval for New Drug Product
Fill Finish Unit for Insulins**

Bengaluru, Karnataka, India, July 16, 2026

Biocon Ltd. (BSE code: 532523, NSE: BIOCON) has received approval from the European Medicines Agency (EMA) for a new drug product fill finish line for Semglee® (insulin glargine) at its insulin manufacturing facility in Malaysia.

Supplies to Europe from this line are expected to begin from Q2FY27.

– Company Spokesperson